Sign inJoin waitlistJoin the waitlist

Angela Jain

Interim Chief, Division of Breast Medical Oncology · Temple University Hospital

Credentials: · · ·

History

Division of Breast Medical Oncology · Temple University Hospital
Present
Division of Gynecologic Medical Oncology · Temple University Hospital
Present
GYN/Well Women's Health Clinical Service Line · Temple University Hospital
Present

Hematology and Medical Oncology
Temple University Hospital
2010–2013
Internal Medicine
Temple University Hospital
2007–2010
Temple University School of Medicine
2003–2007

Research

Ovarian Cancer, Version 2.2020, NCCN Clinical Practice Guidelines in Oncology
Journal of the National Comprehensive Cancer Network · 2021 · 587 citations
NCCN Guidelines® Insights: Ovarian Cancer, Version 3.2022
Journal of the National Comprehensive Cancer Network · 2022 · 346 citations
NCCN Guidelines Insights: Ovarian Cancer, Version 1.2019
Journal of the National Comprehensive Cancer Network · 2019 · 213 citations

Charles Leath
5 papers
Daniela Matei
5 papers
Floor Backes
5 papers
Andrew Berchuck
4 papers · 1 as a resident
Ardeshir Hakam
4 papers
David Gershenson
4 papers
Deborah Armstrong
4 papers
Emese Zsiros
4 papers
Heidi Gray
4 papers
Joyce Liu
4 papers
Kian Behbakht
4 papers
Lainie Martin
4 papers

Clinical trials

Metformin Hydrochloride, Carboplatin, and Paclitaxel in Treating Patients With Recurrent Ovarian, Fallopian Tube, or Primary Peritoneal Cancer
Principal investigator · Withdrawn · Phase 1
Fox Chase Cancer Center
2014
Targeted Therapy Directed by Genetic Testing in Treating Patients With Locally Advanced or Advanced Solid Tumors, The ComboMATCH Screening Trial
Site PI · Recruiting · Phase 2
National Cancer Institute (NCI)
2023–2030
Testing the Addition of Herceptin Hylecta or Phesgo to the Usual Chemotherapy for HER2 Positive Endometrial Serous Carcinoma or Carcinosarcoma
Site PI · Recruiting · Phase 3
National Cancer Institute (NCI)
2022–2027
A Study to Evaluate Safety, Efficacy, and Pharmacokinetics in Participants With Advanced Solid Tumors
Sub-investigator · Unknown · Phase 1, Phase 2
Eutilex
2021–2025